Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of ASP Isotopes Inc. securities, alleging misleading statements regarding the company's technology and operational results during the specified Class Period [1][5]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between October 30, 2024, and November 26, 2024 [1]. - Investors who purchased ASP Isotopes securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by February 3, 2025, to represent other class members in the litigation [1][3]. Group 2: Allegations Against ASP Isotopes - The lawsuit claims that ASP Isotopes overstated the effectiveness of its enrichment technology and the development potential of its uranium facility [5]. - It is alleged that the company also overstated the results of its nuclear fuels operating segment, leading to materially misleading statements about its business and prospects [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages as a result of these misleading statements [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Zeta Global Holdings Corp. during the specified Class Period of the upcoming lead plaintiff deadline on January 21, 2025 [1] Group 1: Class Action Details - Investors who purchased Zeta securities between February 27, 2024, and November 13, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 21, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4] Group 3: Allegations Against Zeta Global - The lawsuit alleges that Zeta made false and misleading statements and failed to disclose critical information, including the use of two-way contracts and round trip transactions to inflate financial results [5] - It is claimed that Zeta utilized predatory consent farms to collect user data, which significantly contributed to the company's growth [5] - The misleading statements about the company's business and operations led to investor damages when the true details became public [5]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Dentsply Sirona Inc. common stock during the specified Class Period, highlighting potential investor compensation opportunities [1][2]. Group 1: Lawsuit Details - The class action lawsuit pertains to Dentsply Sirona Inc. common stock purchases made between December 1, 2022, and November 6, 2024 [1]. - Investors who purchased Dentsply common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by January 27, 2025, to represent other class members in the litigation [1][3]. Group 2: Allegations Against Dentsply - The lawsuit alleges that Dentsply made false and misleading statements regarding its Byte aligner solution, targeting low-income individuals without proper dental care [5]. - It is claimed that the sales strategy led to sales employees selling to patients who were contraindicated for treatment, resulting in inadequate patient onboarding processes [5]. - Reports of patient injuries related to Byte aligners were allegedly ignored by Dentsply, which failed to notify the FDA as required [5]. - The lawsuit asserts that Dentsply materially overstated the goodwill value of Byte and that positive statements about the company's business were misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - A class action lawsuit has been filed against Celsius Holdings, Inc. for allegedly misleading investors regarding its financial performance and sales practices during the specified Class Period from February 29, 2024, to September 4, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Celsius oversold inventory to PepsiCo, leading to a significant decline in future sales and misrepresenting its financial health [5]. - Defendants allegedly made false statements about Celsius' business metrics and financial prospects, which were not as strong as indicated [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering funds for clients [4]. - Investors are advised to select qualified legal counsel with a proven history in similar cases to ensure effective representation [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by January 21, 2025, to represent the class in the lawsuit [1][3].

Core Points - Rosen Law Firm is reminding investors who purchased Edwards Lifesciences Corporation securities between February 6, 2024, and July 24, 2024, of the December 13, 2024, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must act by December 13, 2024, to serve as lead plaintiff [3] Company Details - The lawsuit alleges that during the class period, Edwards provided misleading information regarding its expected revenue for fiscal year 2024, particularly concerning the growth of its Transcatheter Aortic Valve Replacement (TAVR) product [5] - Defendants reportedly made strong commitments to the TAVR platform and claimed significant demand in lower-penetrated markets, which led to investor damages when the true information was revealed [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4] - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]

Core Viewpoint - A class action lawsuit has been filed against Warner Bros. Discovery, Inc. (NASDAQ: WBD) for alleged misleading statements and failure to disclose significant business risks during the Class Period from February 23, 2024, to August 7, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that WBD's negotiations for sports rights with the NBA were likely to cause a significant reevaluation of its business and goodwill [5]. - It is alleged that WBD's goodwill in its Networks segment had deteriorated due to a disparity between market capitalization and book value, along with challenges in U.S. advertising markets and uncertainties in affiliate and sports rights renewals [5]. - The lawsuit suggests that these issues increased the likelihood of WBD incurring billions of dollars in goodwill impairment charges, leading to materially false and misleading public statements about the company's financial prospects [5]. Group 2: Participation Information - Investors who purchased WBD securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Match Group, Inc. securities for the period between May 2, 2023, and November 6, 2024, alleging that the company made materially false and misleading statements regarding its business operations and prospects [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Match Group materially understated the challenges affecting Tinder, leading to an underestimation of the risk that Tinder's monthly active user count would not recover by the time the company reported its Q3 2024 financial results [5]. - Defendants' statements about Match Group's business, operations, and prospects were alleged to be materially false and misleading, lacking a reasonable basis throughout the Class Period [5]. Group 2: Participation Information - Investors who purchased Match Group securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6].

Group 1 - The Rosen Law Firm is reminding purchasers of Lilium N.V. securities about the lead plaintiff deadline of January 6, 2025, for a class action lawsuit [1] - Investors who purchased Lilium securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [3] Group 2 - The lawsuit alleges that during the class period, Lilium's defendants made false or misleading statements regarding the company's fundraising progress, feasibility of obtaining funding, and the imminent insolvency of Lilium and its subsidiaries [5] - The misleading statements led to investor damages when the true details about Lilium's financial situation became public [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]

Core Viewpoint - A class action lawsuit has been filed against Dentsply Sirona Inc. for misleading statements and failure to disclose critical information regarding its Byte aligner product, potentially affecting investors who purchased stock between December 1, 2022, and November 6, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Dentsply targeted low-income individuals lacking access to proper dental care, leading to patients with underlying issues being sold Byte aligners [5]. - It is alleged that the company's sales practices resulted in contraindicated patients being onboarded without adequate checks, despite reports of injuries from Byte users [5]. - Dentsply reportedly failed to notify the FDA about serious injuries related to Byte aligners, which is a legal requirement within 30 days of learning about such issues [5]. Group 2: Investor Information - Investors who purchased Dentsply common stock during the class period may be eligible for compensation without upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion by January 27, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking highly in the industry since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of The Toronto-Dominion Bank (TD) during the class period from February 29, 2024, to October 9, 2024, about the upcoming lead plaintiff deadline on December 23, 2024, for a class action lawsuit related to the bank's anti-money laundering program [3][4]. Group 1: Class Action Details - Investors who bought TD securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 23, 2024 [4]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [5]. Group 2: Allegations Against TD - The complaint alleges that TD provided misleading information regarding the effectiveness of its anti-money laundering (AML) program and the potential consequences of ongoing investigations [6]. - Defendants reportedly made overly positive statements about the AML program while concealing significant failures and the likelihood of punitive measures that could impact TD's growth [7]. - The lawsuit claims that these misleading statements led to shareholders purchasing TD securities at artificially inflated prices, resulting in damages when the true situation was revealed [7].